公开(公告)号：US20070082066A1

公开(公告)日：2007-04-12

申请号：US10841874

申请日：2004-05-07

申请人： Dennis Gierhart ,  Malcolm Grover

发明人： Dennis Gierhart ,  Malcolm Grover

IPC分类号： A61K36/82 ,  A61K36/45 ,  A61K33/32 ,  A61K31/7048 ,  A61K31/704

CPC分类号： A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/30 ,  A61K36/16 ,  A61K36/45 ,  A61K36/82 ,  A61K2300/00

摘要： Zeaxanthin, a dietary carotenoid that occurs in very small quantities in corn, spinach, and other dietary sources, can reduce light hyper-sensitivity and various related conditions (such as migraine or other recurrent headaches) in people who suffer from it. Preferred dosages range from about 10 to about 100 mg per day, depending on the severity of condition, and the weight and medical status of the person. High dosages during an initial “buildup” dosing regimen can promote increased concentrations in the macula and lens, and lower dosages can then be used for maintenance purposes. Lutein may be able to achieve similar results, but because of certain molecular and cellular factors, zeaxanthin is preferable. Additional active agents (such as bilberry or other plant extracts, Vitamins C or E, zinc, etc.) can also be included or coadministered with any such formulations.

摘要翻译： 玉米黄素是玉米，菠菜和其他膳食来源中少量食用的类胡萝卜素，可以降低患有轻度敏感性和各种相关病症（如偏头痛或其他复发性头痛）。 优选的剂量范围为每天约10至约100mg，这取决于病情的严重程度，以及该人的体重和医疗状况。 在初始“积聚”给药方案期间的高剂量可以促进黄斑和晶状体中增加的浓度，然后可以使用较低剂量用于维持目的。 叶黄素可以获得类似的结果，但是由于某些分子和细胞因子，优选玉米黄质。 另外的活性剂（例如越桔或其他植物提取物，维生素C或E，锌等）也可以包括在内或与任何这样的制剂共同施用。

公开(公告)号：US20050147648A1

公开(公告)日：2005-07-07

申请号：US10746403

申请日：2003-12-23

申请人： Dennis Gierhart

发明人： Dennis Gierhart

IPC分类号： A61K31/047 ,  A61K31/07 ,  A61K47/00 ,  A61K31/12

CPC分类号： A61K31/047 ,  A61K9/0048 ,  A61K31/07 ,  A61K2300/00

摘要： Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

摘要翻译： 公开了用于促进眼睛健康，特别是用于预防或治疗黄斑变性的口服制剂，其含有玉米黄质，类胡萝卜素色素和至少两种或多种另外的选自硫辛酸，ω-3脂肪酸，植物的眼睛活性营养物质 衍生的化合物如黄酮，花青素或多酚，牛磺酸，肉碱，辅酶Q10，肌肽以及刺激谷胱甘肽生成的营养物质。 公开了用于鉴定与玉米黄质以协同增效方式相互作用的眼部活性营养物的方法，以提供比仅由玉米黄质提供的更好和更有效的眼睛健康保护。 其他任选的试剂包括锌，维生素E和维生素C.

公开(公告)号：US20060039954A1

公开(公告)日：2006-02-23

申请号：US11133125

申请日：2005-05-18

申请人： Dennis Gierhart ,  C. Dorey ,  Patrick Kelly

发明人： Dennis Gierhart ,  C. Dorey ,  Patrick Kelly

IPC分类号： A61K47/00 ,  A61K33/32 ,  A61K31/375 ,  A61K31/355 ,  A61K31/12

CPC分类号： A61K45/06 ,  A23L33/105 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/12 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00 ,  A23V2250/21 ,  A23V2250/1642 ,  A23V2250/712 ,  A23V2250/708

摘要： Formulations marketed to elderly consumers for preventing or treating age-related eye diseases such as macular degeneration are modified in various four ways, compared to the formulations tested in the first “Age-Related Eye Disease Study” (AREDS-1) clinical trial. Zinc dosages are substabtially reduced, to reduce the risk of Alzheimer's disease and other neurotoxic damage in the brains of elderly people, and zeaxanthin is substituted for a substantial portion of any beta-carotene. Additional useful agents are also disclosed.

摘要翻译： 与在第一期“年龄相关眼病研究”（AREDS-1）临床试验中测试的配方相比，以老年消费者出售用于预防或治疗与年龄相关的眼睛疾病如黄斑变性的配方以四种方式进行了修改。 锌剂量可以降低，以降低老年人脑中阿尔茨海默病和其他神经毒性损伤的风险，而玉米黄质则取代了大部分的β-胡萝卜素。 还公开了其它有用的试剂。

公开(公告)号：US20050171212A1

公开(公告)日：2005-08-04

申请号：US10972699

申请日：2004-10-23

申请人： Dennis Gierhart

发明人： Dennis Gierhart

IPC分类号： A61K20060101 ,  A61K31/045 ,  A61K31/12 ,  A61K31/205 ,  A61N1/30 ,  A61N5/06

CPC分类号： A61N5/062 ,  A61F9/008 ,  A61F2009/00863 ,  A61K31/045

摘要： Pre-treatment using a xanthin carotenoid (preferably 3R,3′R-zeaxanthin) can improve the benefits and efficacy of photodynamic therapy (PDT), which uses a light-activated drug (such as verteporfin) in patients who suffer from unwanted retinal blood vessel growth, including the “wet” (exudative) form of macular degeneration. Before a PDT treatment, patients are given a regimen of orally-ingested zeaxanthin for a period of at least 1 and preferably at least 2 to 3 weeks, at dosages of at least 3 and preferably at least 10 milligrams per day. Since zeaxanthin imparts a yellowish color to the macula, a preferred dosage should increase a patient's macular pigment density before the PDT treatment is performed.

摘要翻译： 使用黄嘌呤类胡萝卜素（优选3R，3'R-玉米黄质）的预处理可以改善在患有不想要的视网膜血液的患者中使用光激活药物（例如维替泊芬）的光动力治疗（PDT）的益处和功效 血管生长，包括“湿”（渗出）形式的黄斑变性。 在PDT治疗之前，给予患者口服玉米黄质的方案至少1次，优选至少2至3周，剂量为至少3次，优选至少10mg /天。 由于玉米黄质对黄斑赋予淡黄色，所以优选的剂量应该在进行PDT治疗之前增加患者的黄斑色素密度。

公开(公告)号：US20060089411A1

公开(公告)日：2006-04-27

申请号：US11198114

申请日：2005-08-06

申请人： Dennis Gierhart

发明人： Dennis Gierhart

IPC分类号： A61K31/203 ,  A61K31/12 ,  A61K31/015

CPC分类号： A61K45/06 ,  A61K31/015 ,  A61K31/12 ,  A61K31/203 ,  A61K2300/00

摘要： Zeaxanthin, a natural carotenoid, can improve and increase the ability of enzyme inhibitors that can slow down certain enzymes that are contributing to toxic metabolite accumulation in people who suffer from Stargardt's disease or other lipofuscin disorders. Such enzyme inhibitors include retinoid analogs such as isotretinoin, commonly known by the trademark, ACCUTANE. This drug binds to and inhibits at least two retinal enzymes, known as RPE65 and short chain dehydrogenase, which create surplus metabolites that feed into a pathway that eventually creates toxic metabolites in people with Stargardt's disease. However, isotretinoin treatment alone is not highly effective; therefore, use of zeaxanthin as an adjunctive treatment can improve the efficacy and outcomes of such treatments.

摘要翻译： 玉米黄质，一种天然的类胡萝卜素，可以提高和增加酶抑制剂的能力，可以减慢某些酶，这些酶对患有斯塔格特氏病或其他脂褐素疾病的人群有毒代谢物积累。 这样的酶抑制剂包括维生素A类似物，如异维A酸，商标通常称为ACCUTANE。 该药物结合并抑制至少两种称为RPE65和短链脱氢酶的视网膜酶，其产生多余的代谢物，其进入最终在Stargardt氏病患者中产生有毒代谢物的途径。 然而，单独的异维A酸治疗不是很有效; 因此，使用玉米黄质作为辅助治疗可以提高这些治疗的疗效和疗效。